Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.

Hospital glucose management has long relied on reactive treatment strategies, especially sliding-scale insulin protocols that respond to blood glucose after it has already risen. While this approach remains common, healthcare systems are increasingly exploring AI solutions for inpatient diabetes care that predict glucose changes before they become dangerous. Instead of …

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …

For people with painful diabetic neuropathy (PDN), treatment has traditionally focused on controlling burning, stabbing, and shooting pain. However, emerging research on spinal cord stimulation for diabetic neuropathy raises a more intriguing question: Could neuromodulation also improve sensation? Results from the SENZA-PDN clinical trial suggest that some patients receiving high-frequency …

Managing glucose is rarely simple for people with Type 2 diabetes who receive maintenance hemodialysis. Dialysis can change glucose patterns, insulin needs, and the reliability of familiar measures such as A1C. As a result, clinicians may have an incomplete picture when making treatment decisions. New randomized research on CGM use …

Three decades of advances in diabetes care have transformed how people with type 1 diabetes manage glucose. Insulin pumps, continuous glucose monitoring (CGM), improved insulin analogs, automated insulin delivery, and earlier screening have all changed daily treatment. However, have these advances actually reduced the long-term complications of type 1 diabetes? …

Gestational diabetes is usually treated as a single diagnosis, but growing evidence suggests the biology behind it can vary considerably from one patient to another. Researchers studying gestational diabetes phenotypes have identified metabolic patterns involving differences in insulin resistance, insulin secretion, or both. These findings raise an important question: Could …

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes, but their effects on gastrointestinal motility remain an important clinical consideration. Opioids can also slow gastrointestinal function, raising an obvious question: what happens when patients need both? New research examining GLP-1 and opioid interactions suggests that opioid choice may …

Managing glucose is rarely simple for people with Type 2 diabetes who receive maintenance hemodialysis. Dialysis can change glucose patterns, insulin needs, and the reliability of familiar measures such as A1C. As a result, clinicians may have an incomplete picture when making treatment decisions. New randomized research on CGM use …

Three decades of advances in diabetes care have transformed how people with type 1 diabetes manage glucose. Insulin pumps, continuous glucose monitoring (CGM), improved insulin analogs, automated insulin delivery, and earlier screening have all changed daily treatment. However, have these advances actually reduced the long-term complications of type 1 diabetes? …

Gestational diabetes is usually treated as a single diagnosis, but growing evidence suggests the biology behind it can vary considerably from one patient to another. Researchers studying gestational diabetes phenotypes have identified metabolic patterns involving differences in insulin resistance, insulin secretion, or both. These findings raise an important question: Could …

A1C is one of the most useful tools in diabetes care, but it has an important limitation: it takes time to reflect change. Could a faster-moving marker help clinicians know sooner whether treatment is working? New randomized research on glycated albumin in diabetes offers an intriguing answer. Glycated albumin reflects …

A diabetes app can track meals, count steps, log glucose, and deliver reminders. However, can an app actually help someone turn all that information into lasting daily habits? A recent randomized controlled trial suggests that digital diabetes coaching, with technology supported by ongoing human guidance, may help bridge that gap. …

Does eating more fat automatically mean that more harmful fatty acids will circulate in the blood? A new randomized trial suggests the answer may be more complicated. Researchers studying a low-carb diet for type 2 diabetes found that six months of carbohydrate restriction changed circulating fatty acids in potentially favorable …

Medical nutrition therapy for diabetes is often discussed in terms of A1C, glucose levels, and weight. However, could personalized nutrition also influence inflammation and other aspects of metabolic health? A recent randomized controlled trial offers an intriguing reason to ask that question. Researchers found that individualized medical nutrition therapy with …

Insulin resistance is often discussed as though it were one metabolic problem affecting the entire body equally. However, emerging research suggests the picture is more complex. Tissue-specific insulin resistance means that fat, muscle, the liver, and other tissues may not respond to insulin in the same way. More importantly, resistance …

Charcot foot in diabetes can begin with a warning sign that seems almost contradictory: a foot that is hot, red, and swollen but causes surprisingly little pain. For people with diabetic peripheral neuropathy, reduced sensation may hide the severity of the problem. As a result, patients may continue walking on …